Insider buying last 90 days
No open-market insider purchases were filed for IDXX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IDXX insider filing, plotted on the chart in Gekko.Open IDXX in Gekko
NASDAQ: IDXX
IDEXX Laboratories (IDXX) Stock Analysis & Forecast
Nov 4 close
$698.55+26.51 (+3.9%)
Gekko Brief
AI summaryNov 4 closeIDEXX reported third-quarter results on 2 November, posting comparable earnings per share of $3.96 against an estimate of $3.73, on revenue of $1.21 billion, up 10.0% year over year, led by the Companion Animal Group and continued demand for diagnostic testing platforms. The company raised full-year revenue guidance to 10.1%-10.8%, with VetLab consumables and CAG revenues growing 16.1% and 11.3% respectively over the first nine months. Reaction to the report has been mixed among commentators, with one piece maintaining a buy rating on the diagnostics franchise while another flagged the stock as expensive following the move, alongside a downgrade.
IDXX closed at $698.55, up 3.9%, sitting above both its 50-day average of $541.78 and its 200-day average of $572.27, with the stock recently crossing above the latter. The GekkoIndex reads 33.7, placing it in the Distribution zone after a five-point change of -19.4. Price sits 33.7% above the Gekko Fair Value of $522.37.
The next earnings date falls on 1 February 2027, 88 days out and beyond a typical 20-trading-day hold. Over the last 90 days, Congressional activity shows 1 buy and 0 sales, and holdings include one billionaire holder and one trailblazer holder. Seasonality from this point in the calendar has averaged a 6.1% gain over the next 20 trading days across 5 years, rising in 4 of them. Analyst coverage from 9 firms shows 6 buy and 3 hold ratings, with a consensus target of $694.83, implying -0.5% versus the current price.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
IDEXX Laboratories price vs fair value
Close $698.55200-day averageGekko Fair Value $522.37
IDEXX Laboratories quick facts
- Market cap
- $55.04B
- P/E ratio
- 38.7
- Forward P/E
- 33.3
- EPS, TTM
- $17.34
- Revenue, TTM
- $4.55B
- Profit margin
- 25%
- Dividend yield
- —
- Beta
- 1.54
- Volume
- 1.40M avg 692,399
- 1-year return
- −3.4%
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±5.1%
- 50-day average
- $541.78
- 200-day average
- $572.27
- Next earnings
- Feb 1 before open
- Shares outstanding
- 78.78M
IDEXX Laboratories swing-trade checklist
IDEXX Laboratories scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $698.55 sits between the 50-day ($541.78) and 200-day ($572.27) averages, or the averages disagree.
See the chart - GekkoIndexheadwind
33.7, Distribution
Reading 33.7 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
33.7% above
Price is 33.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 88 days
Next report Feb 1, 2027, 88 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+6.1% on average
From this point in the calendar, the next 20 trading days averaged +6.1% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
IDEXX Laboratories stock chart and price history
IDEXX Laboratories closed at $698.55 on Nov 4, 2026, −3.4% over the past year, inside a 52-week range of $500.61 to $769.98.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +35.5%
- 3 months
- +18.4%
- 6 months
- +20.6%
- 1 year
- −3.4%
The full IDXX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IDXX in Gekko
Follow IDEXX Laboratories through every session
Put IDXX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IDXX in GekkoFree for 7 days. No credit card required.
About IDEXX Laboratories
IDEXX Laboratories develops and sells diagnostic products and services used mainly by veterinary practices, along with buyers in livestock, poultry, dairy, and water testing. It is widely recognized for its veterinary diagnostics, including point-of-care instruments, consumables, and rapid assay kits used to test companion animals, alongside laboratory testing and consultation work, imaging tools, and practice management software for clinics.
The business is arranged into groups covering companion animal diagnostics, water quality testing, and livestock, poultry, and dairy health monitoring, with further offerings beyond these core areas. Its water testing line includes tests such as Colilert, Colilert-18, Colisure, Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray, used to check for contaminants like coliforms and E. coli. IDEXX also makes instruments for blood gas and electrolyte analysis, chemistry and hematology testing, and SARS-CoV-2 RT-PCR tests, reaching both veterinary and human diagnostic customers, including independent clinics and larger veterinary groups. Sales run through its own marketing, service, and technical teams, as well as outside distributors and resellers.
Founded in 1983, IDEXX Laboratories is headquartered in Westbrook, Maine, and its shares are listed on the NASDAQ under the ticker IDXX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- idexx.com
IDEXX Laboratories GekkoIndex: the smart money zone
IDEXX Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 33.7, in the Distribution zone, down 19.4 points over five sessions.
33.7Distribution
Down 19.4 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +0.1% | +1.7% | ||
| Accumulation | 280 | +0.2% | 0.0% | ||
| Neutral | 347 | +0.1% | +0.3% | ||
| Distribution (current zone) | 35 | −0.1% | +2.1% | ||
| Selling | 1 | Too few readings yet | |||
Average IDXX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the IDXX price, zone by zone.Track IDXX in Gekko
Is IDEXX Laboratories stock overvalued? Gekko Fair Value
IDEXX Laboratories trades 33.7% above Gekko Fair Value of $522.37, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what IDEXX Laboratories shares are worth, recalculated every trading day.
$522.37
Gekko Fair Value, Nov 4, 2026
33.7% Overvalued
At the end of Aug 2026 the price was 20.8% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open IDXX in Gekko
IDEXX Laboratories insider and Congress trading
No open-market insider purchases were filed for IDEXX Laboratories, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 25 |
From congressional disclosures, which report amounts as ranges.
Buybacks
IDEXX Laboratories has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $346.8M
- As a share of market cap
- 0.63%
- Trailing four quarters
- $1.18B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold IDXX.
0added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
IDEXX Laboratories earnings: next date and track record
IDEXX Laboratories reports on Feb 1, 2027, before the open (88 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 1, 2027
Expected before the open, 88 days away
- EPS estimate
- $3.36
- Revenue estimate
- $1.18B
8 of 8reports beat the EPS estimate
±10.9%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 2, 2026 | $3.96 est $3.73 | $1.21B est $1.19B | +21.9% |
| Aug 4, 2026 | $4.27 est $3.95 | $1.22B est $1.20B | +3.0% |
| May 5, 2026 | $3.47 est $3.41 | $1.14B est $1.12B | +2.9% |
| Feb 2, 2026 | $3.08 est $2.94 | $1.09B est $1.07B | −5.7% |
| Nov 3, 2025 | $3.40 est $3.14 | $1.11B est $1.07B | +14.7% |
| Aug 4, 2025 | $3.63 est $3.28 | $1.11B est $1.06B | +19.9% |
| May 1, 2025 | $2.96 est $2.85 | $998.4M est $997.1M | +9.1% |
| Feb 3, 2025 | $2.62 est $2.39 | $954.3M est $935.1M | +10.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
IDEXX Laboratories stock forecast and analyst price targets
Analysts’ average 12-month price target for IDEXX Laboratories is $694.83, −0.5% from the last close, from 9 firms rating the stock in the last 90 days.
$694.83consensus 12-month target, −0.5% from the last close
Now $698.55Avg $694.83
Low $665High $810
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 3 | Stifel Nicolaus | $700 | +0.2% |
| Nov 3 | Jefferies | $770 | +10.2% |
| Nov 3 | UBS | $700 | +0.2% |
| Nov 3 | Morgan Stanley | $810 | +16.0% |
| Nov 2 | Morgan Stanley | $805 | +15.2% |
+2.1%average 20-day move after past Distribution readings
+6.1%average move over the next 20 trading days in the last 5 years
±3.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
IDEXX Laboratories seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, IDEXX Laboratories averaged +6.1% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.8% | 2 of 5 |
| Next 10 trading days | +2.5% | 3 of 5 |
| Next 15 trading days | +4.8% | 4 of 5 |
| Next 20 trading days | +6.1% | 4 of 5 |
| Next 30 trading days | +5.9% | 3 of 5 |
For scale, IDXX’s typical 20-trading-day move in either direction is about 5.1%.
IDEXX Laboratories market cap and key statistics
IDEXX Laboratories’s market cap is $55.04B, with a P/E ratio of 38.7 and revenue of $4.55B over the last twelve months.
Valuation
- Market cap
- $55.04B
- P/E ratio
- 38.7
- Forward P/E
- 33.3
- EPS, TTM
- $17.34
- Gekko Fair Value
- $522.37
Trading
- Volume
- 1.40M
- Avg volume, 20 days
- 692,399
- 52-week high
- $769.98
- 52-week low
- $500.61
- Shares outstanding
- 78.78M
Financials
- Revenue, TTM
- $4.55B
- Profit margin
- 25%
- Return on equity
- 74.2%
- Quarterly earnings growth, YoY
- +17.6%
Risk and income
- Beta
- 1.54
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±5.1%
IDEXX Laboratories stock news this week
Coverage of IDEXX Laboratories this week reads positive: 12 positive, 5 neutral and 0 negative headlines.
- An IRA sale of 500 shares is proposed by IDEXX (IDXX) director Daniel M. Junius.Stock Titan, Nov 4
- IDEXX Laboratories, Inc. (IDXX) Seasonal returns chart - Yahoo FinanceYahoo Finance Singapore, Nov 4
- IDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade)Seeking Alpha, Nov 4
- IDEXX Laboratories: Q3 Results Confirm They Are Best-In-ClassSeeking Alpha, Nov 4
- IDEXX Laboratories, Inc. (IDXX) Seasonal returns chartYahoo Finance UK, Nov 3
- IDEXX Laboratories Inc | 8-K: IDEXX Laboratories Announces Third Quarter ResultsMoomoo, Nov 3
IDEXX Laboratories peers
IDEXX Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
A peer links to its own page where one exists.
IDEXX Laboratories stock FAQ
What is IDEXX Laboratories’s market cap?
IDEXX Laboratories’s market cap is $55.04B at the Nov 4, 2026 close of $698.55, with 78.78M shares outstanding. The shares trade on a P/E ratio of 38.7.
What is the IDEXX Laboratories stock forecast?
The consensus analyst 12-month price target for IDEXX Laboratories is $694.83, −0.5% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is IDEXX Laboratories stock overvalued or undervalued?
On Gekko’s estimate IDEXX Laboratories is overvalued: the Nov 4, 2026 close of $698.55 is 33.7% above Gekko Fair Value of $522.37. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does IDEXX Laboratories report earnings next?
IDEXX Laboratories is expected to report on Feb 1, 2027, before the market opens (88 days away). Analysts expect earnings of $3.36 per share on revenue of $1.18B. IDEXX Laboratories beat the earnings estimate in 8 of its last 8 reports, moving 10.9% on average across the report.
What is IDEXX Laboratories’s 52-week high and low?
IDEXX Laboratories’s 52-week high is $769.98 and its 52-week low is $500.61; it closed at $698.55 on Nov 4, 2026, −3.4% over the past year.
Is IDEXX Laboratories stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (smart money, earnings risk and seasonality), 1 as mixed (trend) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See IDEXX Laboratories the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.